CN114901665A - 三唑并三嗪衍生物在治疗疾病中的用途 - Google Patents

三唑并三嗪衍生物在治疗疾病中的用途 Download PDF

Info

Publication number
CN114901665A
CN114901665A CN202080089936.XA CN202080089936A CN114901665A CN 114901665 A CN114901665 A CN 114901665A CN 202080089936 A CN202080089936 A CN 202080089936A CN 114901665 A CN114901665 A CN 114901665A
Authority
CN
China
Prior art keywords
triazolo
furan
compound
triazine
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080089936.XA
Other languages
English (en)
Inventor
孙三兴
陈正树
叶进启
赵龙
胡崇波
杨勇
管峰
潘姝花
胡宁
潘婷婷
宋国伟
侯方杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Chunhe Pharmaceutical Technology Co ltd
Original Assignee
Zhejiang Chunhe Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Chunhe Pharmaceutical Technology Co ltd filed Critical Zhejiang Chunhe Pharmaceutical Technology Co ltd
Publication of CN114901665A publication Critical patent/CN114901665A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本申请涉及一种三唑并三嗪衍生物或其药学上可接受的溶剂化物或盐在制备治疗疾病的药物中的用途，以及治疗疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (43)

  1. PCT国内申请，权利要求书已公开。
CN202080089936.XA 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途 Pending CN114901665A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019113640282 2019-12-26
CN201911364028 2019-12-26
PCT/CN2020/139690 WO2021129843A1 (zh) 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途

Publications (1)

Publication Number Publication Date
CN114901665A true CN114901665A (zh) 2022-08-12

Family

ID=76573699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080089936.XA Pending CN114901665A (zh) 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途

Country Status (5)

Country Link
US (1) US20230048888A1 (zh)
EP (1) EP4083044A4 (zh)
JP (1) JP2023508182A (zh)
CN (1) CN114901665A (zh)
WO (1) WO2021129843A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056879A (zh) * 1990-05-29 1991-12-11 帝国化学工业公司 吡咯衍生物及其制备方法
US5246932A (en) * 1991-05-23 1993-09-21 Imperial Chemical Industries Plc Heterocyclic compounds
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
US5380714A (en) * 1991-11-25 1995-01-10 Imperial Chemical Industries Plc 2-furyl-triazalo [1,5-a]-[1,3,5]triazines and pyrazolo [2,3-a][1,3,5]triazines
US5789407A (en) * 1993-09-06 1998-08-04 Kyowa Hakko Kogyo Co., Ltd. Method of treating depression with certain triazine derivatives
US20070173505A1 (en) * 2003-04-09 2007-07-26 Hairuo Peng A2a adenosine receptor antagonists
CN111051309A (zh) * 2018-06-26 2020-04-21 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CN111164084A (zh) * 2018-06-26 2020-05-15 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260577A1 (en) 2000-10-09 2005-11-24 Kay Double Detection of neurodegenerative disorders
ATE424194T1 (de) * 2001-04-09 2009-03-15 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056879A (zh) * 1990-05-29 1991-12-11 帝国化学工业公司 吡咯衍生物及其制备方法
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
US5246932A (en) * 1991-05-23 1993-09-21 Imperial Chemical Industries Plc Heterocyclic compounds
US5380714A (en) * 1991-11-25 1995-01-10 Imperial Chemical Industries Plc 2-furyl-triazalo [1,5-a]-[1,3,5]triazines and pyrazolo [2,3-a][1,3,5]triazines
US5789407A (en) * 1993-09-06 1998-08-04 Kyowa Hakko Kogyo Co., Ltd. Method of treating depression with certain triazine derivatives
US20070173505A1 (en) * 2003-04-09 2007-07-26 Hairuo Peng A2a adenosine receptor antagonists
CN111051309A (zh) * 2018-06-26 2020-04-21 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CN111164084A (zh) * 2018-06-26 2020-05-15 浙江春禾医药科技有限公司 可用作a2a受体拮抗剂的三唑并三嗪衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PETER W. R. CAULKETT ET AL.: "Novel adenosine A2Areceptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space", HEJ. CHEM. SOC. PERKIN TRANS., vol. 1, 1 January 1995 (1995-01-01), pages 3427 - 3428 *
ROBERT D. LEONE ET AL.: "Targeting adenosine for cancer immunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 6, 18 June 2018 (2018-06-18), pages 3 *
W. SIHVER ET AL.: "Binding of tritiated and radioiodinated ZM241, 385 to brain A2A adenosine receptors", NUCLEAR MEDICINE AND BIOLOGY, vol. 31, 31 December 2004 (2004-12-31), pages 1 - 2 *

Also Published As

Publication number Publication date
EP4083044A1 (en) 2022-11-02
WO2021129843A1 (zh) 2021-07-01
EP4083044A4 (en) 2024-03-27
US20230048888A1 (en) 2023-02-16
JP2023508182A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
AU2016361326B2 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
US11938124B2 (en) Combination therapy for treatment of cancer
US10689378B2 (en) Triazolopyridine compounds and uses thereof
US20170050967A1 (en) Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
CA3077499C (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
JP2020536917A (ja) キナーゼを調節するための化合物の固体形態
JP6014695B2 (ja) 癌および他の疾患または障害の治療のための医薬組成物
JP2017530940A (ja) Ｐｒｍｔ５阻害剤およびその使用
CN113730412A (zh) 用二氢吡嗪并-吡嗪治疗癌症
CA3103995A1 (en) Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
WO2021004421A1 (zh) 炔类衍生物及其制备方法和用途
TW202116301A (zh) 藥物組合及其用途
JP2023505056A (ja) ジアリール大環状化合物を含む併用療法
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
WO2023186075A1 (zh) 药物组合物、其用途及癌症的治疗方法
WO2020059705A1 (ja) キノリンカルボキサミド誘導体を用いるがん併用療法
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
EP2701690A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
CN114901665A (zh) 三唑并三嗪衍生物在治疗疾病中的用途
US20050182125A1 (en) Pyrrole compounds and uses thereof
JP2017509675A (ja) 癌を処置するためのセファロスポリンの新規誘導体
JP2024511466A (ja) Ａｌｋ－５阻害剤及びその使用
KR20230005175A (ko) Eif4a 억제제 조합물
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
WO2024088392A1 (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination